国产减重药“上市潮”闸门打开,跨国巨头如何应对

第一财经
Jul 06

伴随着国产GLP-1减重药玛仕度肽(商品名:信尔美)的商业化落地,国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境,减重药未来价格是否会出现松动也引发关注。  减重药市场迎来“新玩家”  7月3日,信达生物的GLP-1减重创新药玛仕度肽“首方”落地。北京大学人民医院内分泌科主任医师纪立农教授为一名超重合并脂肪肝的患者开出全国首张处方,标志着玛仕度肽...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10